SCHEMBL4135864

SCHEMBL4135864

CC(=O)COc1ccc2ccccc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 1/20 0.71
RAB9A P51151 4/20 0.64
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
PPARG P37231 3/20 0.63
NCOA2 Q15596 3/20 0.63
NCOA1 Q15788 3/20 0.63
NCOA3 Q9Y6Q9 3/20 0.63
HTT P42858 2/20 0.63
NPSR1 Q6W5P4 2/20 0.63
NR2E3 Q9Y5X4 1/20 0.63
NCOR2 Q9Y618 1/20 0.63
HPGD P15428 2/20 0.58
NPC1 O15118 2/20 0.58
POLB P06746 4/20 0.56
RECQL P46063 1/20 0.56
CTDSP1 Q9GZU7 1/20 0.55
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
GALR3 O60755 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27194588 0.85 PTPN7 (0.76) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL25640 0.83 PTPN7 (1.00) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL6563888 0.83 PTPN7 (0.73) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL29367022 0.83 PTPN7 (1.00) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL30360394 0.82 PTPN7 (0.67) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL8127138 0.82 KMT2A (0.54) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL2474817 0.82 PTPN7 (0.67) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL15201762 0.81 PTPN7 (0.96) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL30439679 0.81 PTPN7 (0.71) PTPN7RAB9AMEN1KMT2APPARG
SCHEMBL1725156 0.81 PTPN7 (0.71) PTPN7RAB9AMEN1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0003643-B1 PROCESS FOR THE PREPARATION OF 4-(6-METHOXY-2-NAPHTHYL)-BUTAN-2-ONE; 4-(6-METHOXY-2-NAPHTHYL)-4-HYDROXYBUT-3-EN-2-ONE AND A PROCESS FOR ITS PREPARATION BEECHAM GROUP PLC (GB) 1982-09-29 EP claimed
EP-3235799-B1 OXIME COMPOUND AND HERBICIDE NISSAN CHEMICAL CORP (JP) 2022-02-23 EP disclosed
US-11000033-B2 Ketone or oxime compound, and herbicide NISSAN CHEMICAL CORPORATION (JP) 2021-05-11 US disclosed
US-20190053488-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE NISSAN CHEMICAL CORPORATION (JP) 2019-02-21 US disclosed
US-20170347647-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-12-07 US disclosed
US-20170347647-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-12-07 US disclosed
EP-3235799-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE Nissan Chemical Industries, Ltd. (JP) 2017-10-25 EP disclosed
WO-2016098899-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE 日産化学工業株式会社 2016-06-23 WO disclosed
WO-2015102418-A2 PEPTIDOMIMETIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR TREATING ALLERGIC DISORDERS INCLUDING SAME 이화여자대학교 산학협력단 2015-07-09 WO disclosed
US-RE43802-E1 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2012-11-13 US disclosed
US-7531538-B2 α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2009-05-12 US disclosed
US-20090023664-A1 ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE LLC (US) 2009-01-22 US disclosed
US-7320983-B2 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2008-01-22 US disclosed
US-7232817-B2 α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-06-19 US disclosed
US-7232817-B2 α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-06-19 US disclosed
US-7202258-B2 α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-04-10 US disclosed
US-7202258-B2 α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-04-10 US disclosed
US-20070078173-A1 Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-04-05 US disclosed
US-20070078173-A1 Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-04-05 US disclosed
WO-2004067522-A1 AZAPHENYLALANINE DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS LEK PHARMACEUTICALS D.D. (SI) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11000033-B2 Ketone or oxime compound, and herbicide OR10J3, CYP1B1, CBR3 PTPN7 216/4885RAB9A 698/4885MEN1 3295/4885
US-20090023664-A1 ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS DNPEP, ASPH, PREP PTPN7 3722/4885RAB9A 2203/4885MEN1 3710/4885
US-20070078173-A1 Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors DNPEP, ASPH, PREP PTPN7 3722/4885RAB9A 2203/4885MEN1 3710/4885
US-20190053488-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE OR10J3, CYP1B1, CBR3 PTPN7 209/4885RAB9A 667/4885MEN1 3264/4885
US-20170347647-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE OR10J3, CYP1B1, CBR3 PTPN7 209/4885RAB9A 667/4885MEN1 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.